<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281021</url>
  </required_header>
  <id_info>
    <org_study_id>629.05</org_study_id>
    <secondary_id>BCC-LUN-05-001</secondary_id>
    <nct_id>NCT00281021</nct_id>
  </id_info>
  <brief_title>Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the potential benefit of adding Digoxin to
      erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases. The majority of
      NSCLC patients have advanced disease at the time of diagnosis, which usually requires
      treatment beyond standard first-line chemotherapy. Until recently, patients were limited in
      the number of options available for second-line treatment of NSCLC. In 2004, erlotinib was
      approved by the FDA for second and third-line treatment of NSCLC. Erlotinib is a cancer
      chemotherapy medication that slows the growth and spread of cancer cells in the body.

      Recent research suggests that a medication called Digoxin can sensitize cancer cells to
      respond better to chemotherapy. Digoxin is normally used to treat certain heart conditions by
      helping the heart beat more strongly and regularly and is not approved by the FDA for the
      treatment of NSCLC. Investigators hope that subject response rates to standard erlotinib
      therapy will be significantly improved by the addition of Digoxin.

      The purpose of this study is to determine the tumor response rate and overall survival of
      patients with non-small cell lung cancer treated with a daily regimen of erlotinib (Tarceva)
      plus Digoxin.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis revealed that only 1 patient had a partial response.
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest &amp; Abdomen.</measure>
    <time_frame>Measured every 6 weeks after baseline until disease progression, an average of 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Erlotinib and Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib plus Digoxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib plus Digoxin</intervention_name>
    <description>Each subject will receive erlotinib and digoxin daily until progression.</description>
    <arm_group_label>Erlotinib and Digoxin</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>Digitalis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of non-small cell lung cancer

          -  measurable or evaluable disease

          -  primary tumor must be documented by histopathic analysis

          -  disease recurrences occurring greater than five years after original diagnosis must be
             biopsy proven

          -  treatment with only one prior chemotherapy regimen for advanced disease (one
             additional prior regimen was allowed for neoadjuvant, adjuvant, or neoadjuvant plus
             adjuvant therapy)

          -  serum creatinine &lt; 2mg/dl, or a calculated creatinine clearance &gt; 40cc/min using the
             following formula: (140-age) x WT(kg) x 0.85 (if female 0.72) x creatinine (mg/dl).
             Tests must be done within 28 days prior to registration

          -  must have a CT scan (chest &amp; abdomen) within 4 weeks prior to registration

          -  Zubrod performance status of 0-3

        Exclusion Criteria:

          -  women who are pregnant or nursing

          -  no other prior malignancy is allowed except for: adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II
             cancer from which the patient is currently in complete remission, or any other cancer
             from which the patient has been disease-free for 5 years

          -  history of ventricular fibrillation, sinus node or AV nodal disease, Wolff Parkinson
             White Syndrome, evidence of congestive heart failure, chest pain with exertion,
             hemodynamically significant or life threatening cardiac arrhythmia, or evidence of
             prior myocardial infarction on EKG. EKG must have been done within 28 days prior to
             registration. A normal cardiac stress test within 182 days prior to registration is
             required for all patients over 50 years old or those with abnormal EKG or any history
             of cardiac disease.

          -  hypersensitivity to erlotinib and/or Digoxin

          -  abnormal levels of K, Mg, and/or Ca, or conditions which cause such abnormalities
             (e.g. malnutrition, severe diarrhea, prolonged vomiting, dialysis, GI suction,
             untreated hypothyroidism, and use of diuretics, amphotericin B, steroids, or antacids)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goetz H Kloecker, MD, MSPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center/ University of Louisville</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.browncancercenter.org</url>
    <description>James Graham Brown Cancer Center</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2006</study_first_submitted>
  <study_first_submitted_qc>January 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2006</study_first_posted>
  <results_first_submitted>April 12, 2013</results_first_submitted>
  <results_first_submitted_qc>November 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2014</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Goetz Kloecker</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Digoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient accrual lasted from March 2006 until August 2008 and was stopped early at the time of interim analysis. 24 who completed at least 6 weeks of therapy are presented here.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erlotinib and Digoxin</title>
          <description>Erlotinib plus Digoxin
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erlotinib and Digoxin</title>
          <description>Erlotinib plus Digoxin
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="34" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest &amp; Abdomen.</title>
        <time_frame>Measured every 6 weeks after baseline until disease progression, an average of 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erlotinib and Digoxin</title>
            <description>Erlotinib plus Digoxin
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest &amp; Abdomen.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Erlotinib and Digoxin</title>
          <description>Erlotinib plus Digoxin
Erlotinib plus Digoxin : Each subject will receive erlotinib and digoxin daily until progression.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Goetz Kloecker</name_or_title>
      <organization>James Graham Brown Cancer Center, University of Louisville</organization>
      <phone>502-562-4358</phone>
      <email>ghkloe01@exchange.louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

